Efficacy Endpoint For BioMarin’s Vimizim Faces FDA Panel Scrutiny

Review documents released ahead of a Nov. 19 advisory committee meeting question whether the six-minute walk test is an appropriate endpoint for the Morquio A syndrome treatment, and whether the findings are clinically meaningful.